Kathleen M Sicinski, Vittorio Montanari, Venkata S Raman, Jamie R Doyle, Benjamin N Harwood, Yi Chi Song, Micaella P Fagan, Maribel Rios, David R Haines, Alan S Kopin, Martin Beinborn, Krishna Kumar
The gut-derived incretin hormone, glucagon-like peptide-1 (GLP1), plays an important physiological role in attenuating post-prandial blood glucose excursions in part by amplifying pancreatic insulin secretion. Native GLP1 is rapidly degraded by the serine protease, dipeptidyl peptidase-4 (DPP4); however, enzyme-resistant analogues of this 30-amino-acid peptide provide an effective therapy for type 2 diabetes (T2D) and can curb obesity via complementary functions in the brain. In addition to its medical relevance, the incretin system provides a fertile arena for exploring how to better separate agonist function at cognate receptors versus susceptibility of peptides to DPP4-induced degradation...
March 24, 2021: ACS Central Science